HALO
Halozyme Therapeutics Inc
109.90$
+2.7%
vs. previous close
Closing price · As of: Oct 2, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 97.2% | 94.5% | 98.1% | 98.2% | 97.2% | 96.0% | 95.7% | 83.9% | 40.1% | 43.1% | 52.6% | 32.7% | |
| 37.0% | 23.8% | 25.5% | 32.5% | 13.2% | 21.2% | 25.5% | 10.7% | 12.7% | 6.8% | 5.6% | 5.3% | |
| 81.7% | 59.6% | 78.4% | 90.2% | 80.5% | 74.4% | 63.5% | 67.1% | 19.7% | 19.4% | 28.9% | 5.7% | |
| 5.5% | 17.8% | 6.0% | 4.3% | 6.8% | 10.5% | 16.9% | 8.2% | 12.5% | 13.5% | 14.9% | 17.5% | |
| 3.9% | 5.2% | 5.6% | 1.0% | 5.1% | 5.2% | 10.5% | 4.9% | 5.4% | 7.4% | 6.9% | 7.0% | |
| 1.8% | 2.2% | 1.6% | 0.7% | 1.7% | 1.9% | 1.8% | 0.8% | 4.1% | – | – | – | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | 0.0% | 22.2% | 24.0% | 20.2% | 23.0% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | 29.7% | 27.3% | 19.5% | 38.9% | |
| 75.1% | 76.3% | 112.4% | 59.9% | 43.5% | 83.8% | 74.0% | 82.2% | 90.8% | 95.2% | 82.4% | 98.1% | |
| 14.7% | 34.4% | 20.9% | 25.3% | 33.9% | 15.1% | 72.7% | 10.6% | 7.1% | 6.5% | 6.7% | 7.0% | |
| 30.0% | 12.0% | 6.7% | 14.8% | 20.8% | 3.5% | 68.5% | 8.1% | 0.7% | 0.4% | – | – | |
| 1.8% | 2.5% | 1.4% | 1.5% | 0.9% | 1.1% | 0.3% | 0.1% | 1.0% | 0.7% | 0.5% | 0.8% | |
| 30.0% | 15.4% | 76.2% | 24.1% | 7.9% | 67.7% | – | 71.3% | 81.1% | 86.5% | 73.0% | 84.8% | |
| 24.9% | 23.7% | -12.4% | 40.1% | 56.5% | 16.2% | 26.0% | 17.8% | 9.2% | 4.8% | 17.6% | 1.9% | |
| -271.4% | -265.5% | -223.8% | -100.5% | -120.7% | -106.7% | -81.8% | -5.3% | 7.8% | 5.2% | 17.4% | 2.2% | |
| 73.9% | 69.7% | 48.9% | 26.7% | 32.6% | 25.5% | 24.4% | 13.3% | 7.6% | 7.7% | 6.3% | 4.9% |
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.